Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05740696
Status:
RECRUITING
Last Update Posted:
2023-02-23
First Post:
2023-02-08
Brief Title:
Registry Study for Optimal Management of Liver Failure in the Chinese Population
Sponsor:
First Affiliated Hospital Xian Jiaotong University
Organization:
First Affiliated Hospital Xian Jiaotong University
Study Overview
Official Title:
Registry Study for Optimal Management of Liver Failure in the Chinese Population RESOLVE-C
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RESOLVE-C
Brief Summary:
Liver failure is the most severe form of liver damage caused by viral alcoholic drug-related and ischemia-reperfusion factors often combined with extrahepatic organ damage resulting in a high mortality rate This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics epidemiology of bacterial and fungal infections the impact of sarcopenia on clinical prognosis and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection end-stage liver disease combined with organ failure and early warning of critically ill patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None